Clinical trial
Bexarotene and GM-CSF in Treating Patients With Myelodysplastic Syndrome or…
NCT00425477 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Other · Completed
Key facts
| NCT number | NCT00425477 |
|---|---|
| Title | Bexarotene and GM-CSF in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia |
| Official title | A Phase II Study of Bexarotene + Sargromastastin as Agents of Differentiation in MDS and AML |
| Lead sponsor | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases |
| Intervention type | Biological, Drug, Genetic, Other, Procedure |
| Interventions | sargramostim, bexarotene, cytogenetic analysis, fluorescence in situ hybridization, flow cytometry, laboratory biomarker analysis, biopsy |
| Enrollment | 26 |
| Start date | Nov 1, 2006 |
| Primary completion | Sep 30, 2016 |
| Completion | Sep 30, 2016 |
| First posted | Jan 23, 2007 |
| Last update posted | Oct 5, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: